Stereotactic body radiation therapy is an emerging noninvasive technique for the treatment of oligometastatic cancer. The use of small numbers of large doses achieve a high percentage of local control. The aim of this study was to evaluate the efficacy and tolerability of SBRT for the treatment of lung metastases in a cohort of patients treated between 2008 and 2012 at our institution.A total of 66 patients with oligometastatic lung tumors (single pulmonary nodules in 40 patients; 61\%) were included in the study. SBRT was performed with a stereotactic body frame and a 3-D conformal technique. Forty-nine central tumors received 23 Gy in a single fraction and 54 peripheral tumors received a dose of 30 Gy in a single fraction. The primary end point was local control; secondary end points were survival and toxicity.Median follow-up was 15 months (range, 3-45 months). Local control rates at 1 and 2 years were 89.1\% and 82.1\%, overall survival rates were 76.4\% and 31.2\%, cancer-specific survival rates were 78.5\% and 35.4\%, and progression-free survival rates were 53.9\% and 22\%, respectively. Median survival time was 12 months, and median progression-free survival time was 10 months. Toxicity profiles were good, with 2 cases of Grade 3 toxicity (pneumonitis).SBRT is an effective and safe local treatment option for patients with lung metastases, although it remains investigational; longer follow-up to confirm results is required.
Clinical Outcomes of Single Dose Stereotactic Radiotherapy for Lung Metastases / Osti, Mattia Falchetto; Carnevale, A.; Valeriani, M.; DE SANCTIS, Vitaliana; Minniti, G.; Cortesi, E.; Martelli, M.; MAURIZI ENRICI, Riccardo. - In: CLINICAL LUNG CANCER. - ISSN 1525-7304. - STAMPA. - (2013). [10.1016/j.cllc.2013.06.006]
Clinical Outcomes of Single Dose Stereotactic Radiotherapy for Lung Metastases.
OSTI, Mattia Falchetto;DE SANCTIS, Vitaliana;G. Minniti;E. Cortesi;MAURIZI ENRICI, Riccardo
2013
Abstract
Stereotactic body radiation therapy is an emerging noninvasive technique for the treatment of oligometastatic cancer. The use of small numbers of large doses achieve a high percentage of local control. The aim of this study was to evaluate the efficacy and tolerability of SBRT for the treatment of lung metastases in a cohort of patients treated between 2008 and 2012 at our institution.A total of 66 patients with oligometastatic lung tumors (single pulmonary nodules in 40 patients; 61\%) were included in the study. SBRT was performed with a stereotactic body frame and a 3-D conformal technique. Forty-nine central tumors received 23 Gy in a single fraction and 54 peripheral tumors received a dose of 30 Gy in a single fraction. The primary end point was local control; secondary end points were survival and toxicity.Median follow-up was 15 months (range, 3-45 months). Local control rates at 1 and 2 years were 89.1\% and 82.1\%, overall survival rates were 76.4\% and 31.2\%, cancer-specific survival rates were 78.5\% and 35.4\%, and progression-free survival rates were 53.9\% and 22\%, respectively. Median survival time was 12 months, and median progression-free survival time was 10 months. Toxicity profiles were good, with 2 cases of Grade 3 toxicity (pneumonitis).SBRT is an effective and safe local treatment option for patients with lung metastases, although it remains investigational; longer follow-up to confirm results is required.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.